SLC12A2 variants cause a neurodevelopmental disorder or cochleovestibular defect by McNeill, A. et al.
This is a repository copy of SLC12A2 variants cause a neurodevelopmental disorder or 
cochleovestibular defect.




McNeill, A., Iovino, E., Mansard, L. et al. (17 more authors) (2020) SLC12A2 variants 
cause a neurodevelopmental disorder or cochleovestibular defect. Brain. awaa176. ISSN 
0006-8950 
https://doi.org/10.1093/brain/awaa176
This is a pre-copyedited, author-produced version of an article accepted for publication in 
Brain following peer review. The version of record Alisdair McNeill, Emanuela Iovino, Luke 
Mansard, Christel Vache, David Baux, Emma Bedoukian, Helen Cox, John Dean, David 
Goudie, Ajith Kumar, Ruth Newbury-Ecob, Chiara Fallerini, Alessandra Renieri, Diego 
Lopergolo, Francesca Mari, Catherine Blanchet, Marjolaine Willems, Anne-Francoise 
Roux, Tommaso Pippucci, Eric Delpire, SLC12A2 variants cause a neurodevelopmental 





Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
For Peer Review





Date Submitted by the 
Author:
05-Apr-2020
Complete List of Authors: McNeill, Alisdair; The University of Sheffield, Sheffield Institute for 
Translational Neuroscience
Iovino, Emanuela; University of Bologna
mansard, luke; University of Montpellier
Vache, Christel; University of Montpellier
baux, david; University of Montpellier
bedoukian, emma; CHOP
cox, helen; University of Birmingham Edgbaston Campus
dean, john; University of Aberdeen
Goudie, David; University of Dundee
kumar, ajith; Great Ormond Street Hospital for Children
Newbury-Ecob, Ruth; Bristol Royal Hospital for Children
Fallerini, Chiara; University of Siena
lopergolo, diego; University of Siena
Mari, Fransceca; University of Siena
Renieri, Alessandra ; University of Siena
Blanchet, Catherine; CHU MONTPELLIER, Oto-Rhino-Laryngologie et 
Chirurgie Cervico-Faciale
willems , marjolaine; University of Montpellier
roux, anne; University of Montpellier
PIPPUCCI, TOMMASO; U.O. Genetica Medica - Polyclinic Sant'Orsola-
Malpighi, Bologna, 
delpire , eric; Vanderbilt University School of Medicine
Subject category: Genetics
To search keyword list, use 
whole or part words followed 
by an *:
GENETICS, Genetics: learning disability < GENETICS, Genetics: other < 
GENETICS, Whole-exome sequencing < GENETICS, Neurogenesis < 
SYSTEMS/DEVELOPMENT/PHYSIOLOGY, Vertigo < 
SYSTEMS/DEVELOPMENT/PHYSIOLOGY
 
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
Submitted as a Report to Brain
SLC12A2 variants cause a neurodevelopmental disorder or cochleovestibular defect 
Running title:  SLC12A2 variants in developmental disorders
Alisdair McNeill1, Emanuela Iovino2, Luke Mansard3, Christel Vache3, David Baux3, Emma 
Bedoukian4, Helen Cox5, John Dean6, David Goudie7, Ajith Kumar8, Ruth Newbury-Ecob9, 
Chiara Fallerini10,11, Alessandra Renieri10,11 , Diego Lopergolo10,11, Francesca Mari10,11, Catherine 
Blanchet12 Marjolaine Willems13, Anne-Francoise Roux3,Tommaso Pippucci14, and Eric Delpire15 
 
1. Department of Neuroscience, University of Sheffield, Sheffield, S10 2HQ, UK; Sheffield 
Clinical Genetics Service, Sheffield Children’s Hospital NHS Foundation Trust. 
a.mcneill@sheffield.ac.uk 
2. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
3.  Laboratory of Molecular Genetics, CHU Montpellier, University of Montpellier, 
Montpellier, France
4. Roberts Individualized Medical Genetics center, Children’s Hospital of Philadelphia, 
Philadelphia. PA 19104.
5. Regional Clinical Genetics Unit, Birmingham Women’s and Children’s Hospital NHS 
Foundation Trust, Mindelsohn Way, Birmingham.  B15 2 TG.
6. North of Scotland Genetics Service, Aberdeen Royal Infirmary, Foresterhill, Aberdeen. AB25 
2ZA.
7. East of Scotland Regional Genetics Service, Level 6, Ninewells Hospital, Dundee. DD2 1SY.
8. Clinical Genetics Unit, Great Ormond Street Hospital, Great Ormond Street, London WC1N 
3JH
9. Bristol Regional Genetics Service, St Michael’s Hospital, Southwell Street, Bristol. BS2 8EG. 
10. Medical Genetics, University of Siena, Siena, Italy
11. Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy
12. Centre of Reference for Genetic Sensory diseases, CHU Montpellier, University of 
Montpellier, Montpellier, France
13. Department of Clinical Genetics, CHU Montpellier, University of Montpellier, Montpellier, 
France
14. Medical Genetics Unit, Polyclinic Sant’Orsola-Malpighi University Hospital, Bologna, Italy.
Page 1 of 37
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
15. Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, TN, 
37232, USA. eric.delpire@vanderbilt.edu 
 
Corresponding authors:
Alisdair McNeill, PhD FRCP Edin DCH         Eric Delpire, Ph.D.
Department of Neuroscience Department of Anesthesiology
University of Sheffield Vanderbilt University Medical Center
385a Glossop Road T-4202 MCN, 1161 21st Avenue South
Sheffield, S10 2HQ Nashville, TN 37232-2520, USA
Tel: +44 (0)114 22 22267 Tel: +1-615-343-7409
a.mcneill@sheffield.ac.uk  eric.delpire@vanderbilt.edu
Page 2 of 37




The SLC12 gene family consists of SLC12A1 - SLC12A9, encoding electroneutral cation-
coupled chloride cotransporters. SCL12A2 has been shown to play a role in corticogenesis and 
therefore represents a strong candidate neurodevelopmental disorder gene. Through trio 
exome sequencing we identified de novo mutations in SLC12A2 in 6 children with 
neurodevelopmental disorders. All had developmental delay or intellectual disability ranging 
from mild to severe. Two had sensorineural deafness. We also identified SLC12A2 variants in 
3 individuals with non-syndromic bilateral sensorineural hearing loss and vestibular 
areflexia. The SLC12A2 de novo mutation rate was demonstrated to be significantly elevated 
in the Deciphering Developmental Disorders cohort. All tested variants were shown to reduce 
cotransporter function in Xenopus laevis oocytes. Analysis of SLC12A2 expression in fetal 
brain at 16-18 weeks post conception revealed high expression in radial glial cells, compatible 
with a role in neurogenesis. Gene co-expression analysis in cells robustly expressing SLC12A2 
at 16-18 weeks post conception identified a transcriptomic program associated with active 
neurogenesis. We identify SLC12A2 de novo mutations as the cause of a novel 
neurodevelopmental disorder and bilateral non-syndromic sensorineural hearing loss and 
provide further data supporting a role for this gene in human neurodevelopment.    
Keywords
Corticogenesis, neurodevelopmental disorder, de novo mutation, exome, brain. 
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Neurodevelopmental disorders (NDD) affect 1-5% of the population and demonstrate clinical and 
aetiological heterogeneity (Wright et al., 2015). De novo mutations (DNM) are associated with 
NDD in around 25% of cases (McRae et al., 2017). Corticogenesis is the process by which neuronal 
progenitors proliferate and migrate to form the cerebral cortex (Urbán and Guillemot, 2014). 
Corticogenesis is tightly regulated by transcriptional programs, with temporal and spatial regulation 
of gene expression. In humans corticogenesis begins around embryonic day 42 and is largely 
completed by birth (Urbán and Guillemot, 2014). Many of the genes affected by DNM in NDD play 
a role in corticogenesis (McRae et al., 2017; Zawerton et al., 2019), and corticogenesis genes are 
strong candidates for NDD.  The SLC12 gene family consists of SLC12A1 - SLC12A9, encoding 
electroneutral cation-coupled chloride transporters (Arroyo et al., 2013).  Several of these genes are 
known to cause human disease (Table S1). There is no clear gene-disease relationship for SLC12A2 
(NKCC1). However, SCL12A2 has been shown to play a role in corticogenesis (Young et al., 2012) 
and the excitatory-inhibitory GABA switch during brain development (He et al., 2014).  SLC12A2 
represents a good candidate gene for NDD. 
Study of an Slc12a2/NKCC1 null mouse demonstrated that the transporter is a key mechanism in 
the accumulation of the K+-rich endolymph in the inner ear (Delpire et al., 1999). Absence of 
NKCC1 causes sensorineural deafness and balance deficits. Little is known about a brain phenotype 
in the NKCC1 knockout mouse. However, NKCC1 expression in central neurons is 
developmentally regulated in rodents (Plotkin et al., 1997). Expression is likely highest when the 
neurons are born in the subventricular zone at a time when the intracellular chloride (Cl-)  
concentration is highest (Ben-Ari, 2012). High Cl- facilitates the development of GABA-mediated 
giant synaptic potentials, by which GABA excites developing neurons to promote growth and 
synapse formation when glutamatergic inputs have not yet developed (Ben-Ari, 2012). Disruption 
of NKCC1 expression during development is likely to have consequences for brain development.
SLC12A2 undergoes alternative splicing, with 8-isoforms identified by the Genotype-Tissue 
Expression Project (GTEx)(Figure S1)(Stranger et al., 2017).  The full-length isoform is 27 exons, 
with exon 21 being spliced out in the other major isoform.   In mouse cochlea only the exon 21 
containing isoform is expressed (Dixon et al., 1999).  Deafness in the sy mouse is due to an exon 
21 frameshift in Slc12a2 (Dixon et al., 1999). In the brain both exon 21 containing and exon 21 
deleted isoforms are expressed (Morita et al., 2014).  Here, we describe 6 patients with DNM in 
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SLC12A2 associated with a NDD and 3 with bilateral sensorineural hearing loss (BLSNHL) and 
exon 21 variants.   
Methods
Ascertainment of individuals with SCL12A2 variants
Probands with protein altering SNVs in SLC12A2 were identified in patients 1-5 by exome 
sequencing in the Deciphering Developmental Disorders study (DDD)(Wright et al., 2015). 
Subjects 6-9  were identified via Genematcher (Sobreira et al., 2015).  Written consent was obtained 
from parents/guardians. 
In silico assessment of pathogenicity of SCL12A2 variants 
The effects of SLC12A2 variants were assessed using multiple  in silico tools (Schwarz et al., 2010; 
Shihab et al., 2013). The excess in occurrence of de novo SLC12A2 protein-altering variants in DDD 
was assessed using DenovolyzeR(Ware et al., 2015), which compares the observed:expected 
number DNMs to identify an elevated de novo mutation rate for a given gene. Spatial clustering of 
missense SLC12A2 DNMs was assessed using Denovonear, which calculates the probability of the 
observed spatial pattern of DNM arising by chance. We used MuPiT, which maps the effect of 
SNVs onto 3D-protein structures, to visualise the structural effects of DNMs (Niknafs et al., 2013).
Transcriptomic study of SLC12A2 expression in developing human brain
Variations in SLC12A2 transcript levels in the human brain among different developmental stages 
and anatomical regions were investigated using data from the BrainSpan Atlas of the Developing 
Human Brain (Miller et al., 2014). Single cell RNA (scRNA) sequencing data from the human brain 
at 16-18 weeks gestation was obtained from (Pollen et al., 2015).  NetworkAnalyst, which uses 
protein-protein interaction networks to analyse gene expression studies,  was  used to explore 
transcriptomic differences in scRNA data between SLC12A2 expressing and non-expressing cells 
(Xia et al., 2015). 
In silico study of expression of SLC12A2 splice isoforms 
RNA-seq data from the BrainSpan Atlas of the Developing Human Brain was used to analyse levels 
of SLC12A2 exon expression during brain development.  RNA-seq data from developing mouse 
cochlea was examined for alternative splicing of SLC12A2 during cochlear development (Ranum et 
al., 2019).    
In vitro assessment of NKCC1 ion transporter function
NKCC1 function was assessed through K+ influx measurements into Xenopus laevis oocytes 
injected with wild-type or mutant NKCC1 cRNA. Detailed protocols have been published and 
summarised in the supplementary methods (Delpire et al., 2011). 
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Identification of SLC12A2 variants in children with neurodevelopmental disorders
Through trio exome sequencing, we identified 6 children with NDD and DNM in SLC12A2.  
Detailed clinical reports are in the supplementary material and Table 1. All had intellectual disability 
or developmental delay varying from mild to severe. Three had an autistic spectrum disorder. 
Patient 1 had cerebral cortical dysplasia on brain MRI. Patient 5 agenesis of the corpus callosum. 
Two had BLSNHL. Patient 4 had spastic diplegia and patient 5 spastic quadriparesis.  In addition 
we identified 3 individuals  from 2 unrelated families with congenital non-syndromic BLSNHL and 
an SCL12A2 variant (Table 1). There was no shared facial dysmorphology. None had a pathogenic 
copy number variant, any additional candidate DNM (Table  S2) or causal variant in a deafness 
gene.       
  
In silico assessment of SLC12A2 variants supports pathogenicity 
Seven of the 8 identified SLC12A2 variants were de novo and all had CADD scores > 20 (Table 1, 
Figure 1a). The missense variants affected evolutionarily conserved residues, conserved between 
SLC12 gene family members (Figure S2). We assessed whether the DNM rate in the DDD cohort 
was elevated. We collected all 8 SLC12A2 protein-altering DNMs (the 5 pathogenic variants plus 3 
variants predicted to be benign, table in data supplement) in DDD. Using DenovolyzeR, we showed 
a 9.62-fold DNM enrichment in SLC12A2 (p= 2.71e-06, after correction for multiple testing p= 
0.05). 
SLC12A2 sequence data from the gnomAD database demonstrated significant constraint for PTV 
in SLC12A2 (58.7 expected versus 11 observed, pLI = 0.96, observed:expected 0.19 [0.12-0.31]), 
but not for missense SNVs (594 observed versus 430 expected, Z = 2.4, observed:expected 0.72 
[0.67-0.78]). We then used gnomAD data to examine the spatial distribution of missense SNVs in 
SLC12A2, to look for differential prevalence of missense variants in protein domains (implying 
regional constraint). There was no difference in the percentage of residues with a synonymous 
variant in the functionally important domains (transmembrane domains)(Chew et al, 2019) and 
domains of no known function (19% vs 22%, p = 0.13). In the functionally significant domains, 
35% of residues had a missense variant compared to 43% of residues in the domains of no known 
functional significance (chi-squared, p = 0.0037). In addition, constraint data from (Samocha et al., 
2017) indicates that amino acids 1 – 836 are depleted of missense variants (observed 173, expected 
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294.8, ratio 0.58, chi squared 50.3) while the remainder of the protein is not. This suggests constraint 
of missense variation in the functionally significant domains of SLC12A2.       
Pathogenic SLC12A2 variants alter NKCC1 activity
To assess the functional significance of the mutations, we injected wild-type NKCC1 and mutant 
NKCC1 cRNAs in Xenopus laevis oocytes and performed standard K+ influx measurements under 
isotonic (basal) and hypertonic (stimulated) conditions.  We used the mouse cDNA, which is 95% 
conserved compared to human SLC12A2. For every mutation tested, Figure S2 demonstrates 
homology of the mutated and surrounding residues within the Slc12a transporter family and among 
NKCC1 proteins from 6 species (sea urchin and five vertebrates).  All tested mutations 
demonstrated significant reduction in K+ influx (Figure 2, detailed results in supplementary 
material). 
 
Spatial proximity of SLC12A2 missense DNMs altering NKCC1 activity
We wondered whether DNMs (p.(Ala327Val), p.(Arg410Gln), p.(Asn376Ile), p.(Ala379Pro), 
p.(Glu980Lys)) clustered within the protein. Clustering analysis with Denovonear demonstrated a 
greater spatial proximity within the protein than expected by chance (p= 0.027), with the majority 
of DNMs falling into transmembrane domains (Figure 1b). We then used MuPiT to map these 
DNMs onto NKCC1 three-dimensional protein structure, showing all DNMs embedded within the 
transmembrane core of the protein (Figure 1c). 
Expression of SLC12A2 in developing human brain supports a role in neurogenesis 
We next examined SLC12A2 expression in developing human brain using microarray data from the 
BrainSpan atlas. SLC12A2 expression was significantly higher (Mann-Whitney U-test, Z= -8.36 p 
< 0.001) in neuroanatomical regions with high neurogenesis (ventricular zone, subventricular zone) 
compared with regions of less active neurogenesis (cortical plate, subplate) at 15-16 weeks gestation 
(Figure 3a). For a range of brain expressed genes with no known role in neurogenesis there was no 
differential expression in neurogenic niches (data not shown).     
Single-cell RNA sequencing data from 16-18 weeks gestation fetal brain was then used to identify 
populations of cells which express SLC12A2 during development. The marker genes defined in 
Pollen et al were used to identify radial glia  (e.g. PAX6, SOX2, VIM), intermediate progenitors (e.g. 
EOMES, RBFOX1) and neurons (e.g. MYT1L, NEUROD1, SATB2). SLC12A2 expression was 
significantly higher in radial glia than in intermediate progenitors (mann-whitney u-test, Z = -3.3, p 
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= 0.001) or neurons (z = -5.2, p < 0.001), but did not differ between intermediate progenitors and 
neurons (z = -1.06, p = 0.28, Figure 3b). In radial glial there was no expression of other SLC12 gene 
family members known to have a role in neuronal development or function. This suggests other 
SLC12A2 family members cannot compensate for reduction in SLC12A2 function associated with 
SLC12A2 DNM.       
In silico study of expression of SLC12A2 splice isoforms 
RNA-seq data from BrainSpan quantifies levels of exon expression.  Figure S3a demonstrates an 
excess of transcripts for exon 1-28 compared to exon 21 in human fetal brain.  SLC12A2 isoforms 
lacking exon 21 therefore exist in developing human brain.   RNA-seq of developing mouse cochlea 
demonstrated no alternative splicing of exon 21; the exon 21 containing isoform is the only 
transcript expressed (Figure S3b).     
SLC12A2 expressing cells display transcriptomic profiles of active neurogenesis
To investigate the functional properties of SLC12A2 expressing cells we used the single cell RNA 
sequencing data from Pollen et al to select cells robustly expressing SLC12A2 (>100 counts per 
million) and those with no SLC12A2 expression. This was done agnostic to cell type.  We then used 
NetworkAnalyst to identify differentially expressed genes in SLC12A2 expressing cells.  This 
identified 589 differentially expressed genes (corrected p-value < 0.05 with > 2 fold difference in 
expression). Images of networks generated and a full list of enrichment terms is in the supplemental 
data (Figure S4).    
Given that we were analysing scRNA data from fetal brain, we used tissue specific (brain cortex) 
co-expression network analysis to form a network from differentially expressed genes. 
NetworkAnalyst created a gene co-expression network (supplementary data).  This network was 
enriched for Reactome terms (e.g. L1CAM interaction and axon guidance [both FDR corrected p = 
0.00085]) and Gene Ontology (GO) biological process terms (e.g. axonogenesis [p = 0.0027], 
neurodevelopment [p = 0.0036]) relevant to neurodevelopment.  We then used the label propagation 
algorithm to identify 5 modules within the network (supplementary data). Details of the enrichment 
analysis of all 5 modules is in the data supplement.  Module 1 (coloured blue) was the largest (435 
genes, Figure S4a). It was enriched for Reactome term L1CAM interaction (p = 0.010) and GO 
biological process terms cytoskeleton dependent intracellular transport (p = 0.00005) and synaptic 
transmission (p = 0.00072) as well as Panther biological process term nervous system development 
(p = 0.017).  Module 2 (coloured red, 104 genes, Figure 4b) was enriched for the Reactome term 
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notch-HLH transcription pathway (p = 0.0016) and GO biological process terms for neuron 
formation (neuron differentiation, generation of neurons, neurogenesis, nervous system 
development, all p=0.01).  Modules 3 (coloured white, 123 genes), 4 (coloured green, 117 genes) 
and 5 (coloured yellow, 123 genes) were not enriched for neurogenesis terms. SCL12A2 expressing 
cells manifest a transcriptomic program suggesting an active role in neurogenesis.  
Discussion
We describe 6 individuals with a pleiotropic NDD associated with DNM in SCL12A2.  All had 
developmental delay, ranging from mild to severe. 3 had autistic spectrum disorder. In addition we 
identified 3 patients with BLSNHL and no NDD. Two individuals with likely pathogenic variants 
in SLC12A2 have previously been reported. We described a female patient with a PTV in exon 22 
of SLC12A2 (Delpire et al., 2016). She presented with lung, gastrointestinal tract, endocrine and 
exocrine gland deficits with seizure like episodes and EEG abnormalities, but no hearing 
impairment. Recently, a 5-year old boy with uniparental disomy for chromosome 5 with a 22 kb 
deletion of SLC12A2 was described with bilateral sensorineural deafness, global developmental 
delay and failure to thrive (Macnamara et al., 2019). Our report confirms that SLC12A2 variants are 
associated with a pleiotropic NDD and exon 21 variants with BLSNHL. 
Pleiotropy is well recognised in NDD (McRae et al., 2017). The explanation for pleiotropy 
associated with SLC12A2 is unclear. The severe phenotype in the boy reported by MacNamara et 
al is likely related to the presence of a homozygous variant in SLC12A2, combined with the effects 
of uniparental disomy for chromosome 5. Patients 3 and 5 in our series had PTV and their 
phenotypes were subjectively more severe than those of the patients with missense variants. A larger 
series of SLC12A2 variants will be required to confirm any genotype-phenotype correlation. Patient 
7 was 47,XYY. The contribution of this is not clear. XYY-syndrome has been associated with a 
mild reduction in intelligence quotient (IQ)(Green et al., 2019). There is no clear association 
between  BLSNHL or tongue fasciculations and XYY-syndrome.  The cochlea expresses only the 
SLC12A2 isoform containing exon 21, suggesting exon 21 plays a critical developmental role in 
cochlea (Dixon et al., 1999) and explaining why exon 21 variants cause BLSNHL. Notably, 
deafness in the sy mouse is due to an exon 21 Slc12a2 mutation (Dixon et al., 1999).   In human 
fetal brain, significant amounts of the SLC12A2 isoform lacking exon 21 are expressed (Morita et 
al., 2014).  This may compensate for deleterious effects of exon 21 variants and explain why exon 
21 variants do not cause a NDD.    
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In both murine models (Magalhães and Rivera, 2016) and cell systems (Young et al., 2012), loss of 
Slc12a2/NKCC1 has been shown to inhibit neurogenesis. SLC12A2 is highly expressed in areas of 
active neurogenesis and SLC12A2 expression is higher in radial glia than in intermediate progenitor 
cells or neurons at 16-18 weeks gestation. Transcriptomic profiling indicates that SLC12A2 
expressing cells (at 16-18 weeks gestation) manifest a transcriptomic program reflecting active 
neurogenesis. Reduced function of SLC12A2 might result in a NDD by altering the delicate process 
of corticogenesis, and/or by dysregulating the excitatory-inhibitory GABA switch.   
          
The phenotype of humans with SLC12A2 variants has similarities to animal models. An slc12a2 
null zebrafish displays collapse of the otic vesicle with reduced endolymph (Abbas and Whitfield, 
2009). This paper did not describe the brain phenotype. The otic malformation in the zebrafish 
model has relevance to the hearing loss in SLC12A2 variant carriers. Several Slc12A2 murine 
models exist. We initially reported an Slc12A2 null mouse with cochlear malformations, loss of hair 
cells and hearing impairment (Delpire et al., 1999). The brain phenotype in this mouse has not been 
studied extensively. Reduced neuronal prolif ration has been demonstrated in the lateral ganglionic 
eminence of the null mouse (Magalhães and Rivera, 2016), and NKCC1 knockdown by short 
hairpin RNA reduced neuronal proliferation in the murine subventricular zone (Young et al., 2012). 
The similarities between animal models and the human phenotype of SCL12A2, the role of SLC12A2 
in neuronal development, the results of in silico analyses and the effects of the SNVs on NKCC1 
biochemical function provide strong support for a causal role of SLC12A2 variants in NDD and 
BSNHL.   
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Figure 1. SLC12A2 missense variants.  
A. Chart summarising frequency of clinical features in children with SLC12A2 de novo mutations 
and a NDD. B. Schematic representation of NKCC1 with 12 transmembrane domains and inverted 
5 TMs + 5 TMs symmetry (shaded TMs), followed by TM11 and TM12 (white TMs). The position 
of patient mutations is indicated in red. C. Three dimensional structure of NKCC1 demonstrating 
location of missense variants at core of protein, with high potential to disrupt protein structure.
Figure 2. Functional analysis of NKCC1 mutation in Xenopus laevis oocytes. A-B. Box plots 
demonstrating K+ influx measured in oocytes injected with water (negative control), water 
containing 15 ng wild-type (control) or mutant mouse NKCC1 cRNA. Horizontal line represents 
median, extent of box demonstrates interquartile range and whiskers minimum and maximum. K+ 
fluxes were measured under basal isosmotic (200 mOsM) or stimulated hyperosmotic (270 mOsM) 
conditions and are expressed in pmoles K+ per oocyte per hour.  As the mutants were tested in 
different experiments on different oocytes, each mutant flux is accompanied by its own control flux. 
Statistical differences were determined using one way ANOVA. Each experiment represents 20-25 
oocytes per mutation. Note that the mouse residue numbers are slightly different from human.
Figure 3. Transcriptomic analysis of SCL12A2 expression in developing human brain. 
Figure 3. Transcriptomic analysis of SCL12A2 expression in developing human brain. 3a. Box 
plots of microarray data comparing SLC12A2 expression in neuroanatomical regions of high and 
less active neurogenesis at 15 weeks gestation. Horizontal lines represent median, extent of box 
interquartile range and whiskers minimum and maximum.  Expression is significantly higher in 
areas of active neurogenesis (*).  3b. Single cell RNA sequencing data demonstrating significantly 
higher expression of SLC12A2 in radial glia cells (RGC) compared to intermediate progenitor 
cells (IPC)(mann-whitney u-test, Z = -3.3, p = 0.001) and neurons (z = -5.2, p < 0.001).  Units are 
counts per million reads (CPM).
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Figure S1. SLC12A2 splice isoforms. 
Eight SLC12A2 isforms are identified by GTEx https://www.gtexportal.org/home/gene/SLC12A2.  
Note canonical isoform ENST00000262461.6 has 27 exons.  ENST00000343225.4 has exon 21 
spliced out and represents the minor isoform found in the developing brain.  
 
Figure S2. Sequence alignment of SLC12 gene family members. 
The amino acid sequences of NKCC1 from eight species were aligned using VectorNti Suite 6.0 
(Invitrogen). Portions representing the regions of interest were selected as follows: in A, a portion 
of TMD2 highlighting the conservation of the Ala327 residue; in B, a portion of TMD4 showing 
conservation of Arg410; in C, amino acids within a portion of the carboxyl-terminus showing 
conservation of Trp892; in D, portion of TM3 showing conservation of residues Asn376 and 
Ala377; and in E, a portion of the carboxyl-terminus showing some degree of conservation of 
residues Glu979 and Glu980. To assess conservation between the different members of the SLC12A 
gene products, the amino acids from human NKCC1, NKCC2, NCC, and KCC1-4 were also 
aligned. In F, residue Ala327 is less conserved among the different cotransporters; in G, Arg410 is 
highly conserved; in H, Trp758 is also a highly conserved residue; and in I, Asn376 and Ala377 are 
only conserved within the Na+-dependent cotransport rs. Identical residues across are highlighted 
by yellow background, whereas conserved substitutions are shown in green or blue background. 
Non-conserved residues are shown in white background.  
Figure S3. Expression of alternatively spliced exons and isoforms of SCL12A2. 
a. The ratio of exon 21 expression to expression of all other 27 exons of SLC12A2 is <1.0 in 
the first and second trimester of pregnancy.  This demonstrates the presence of transcripts 
which do not contain exon 21.
b. Image captured from https://morlscrnaseq.org/ an atlas of long-read single cell RNA 
expression data from murine inner ear.  Sashimi plot demonstrates no alternative splicing 
events at exon 21.  The only transcript expressed in mouse cochlea therefore contains exon 
21. 
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Figure S4. Gene co-expression network analysis of single cell RNA data from SLC12A2 
expression cells. 
A. Figure shows module 1 identified by gene co-expression network based on differentially 
expressed genes created by NetWorkAnalyst.   The degree filter was used so that only hub 
genes are shown in this figure. 
B. Table of significantly enriched terms for whole network. 
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Table 1. Summary of clinical and genomic data for SLC12A2 variant carriers. 
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6












g. 5 127420201dup g. 5 127466845delinsCT
c.DNA variant
NM_001046.3
c.980C>T c.1229G>A c.2675G>A c.1127A>T c.555dupG c.1135_1136delGCinsC
T
ACMG criteria 4 4 5 4 4 4
Inheritance De novo De novo De novo De novo De novo De novo
Amino acid 
change
p.(Ala327Val) p.(Arg410Gln) p.(Trp892*) p.(Asn376Ile) p.(His186AlafsTer1
7)
p.(Ala379Leu) 
Exon (of 27) 4 6 18 5 1 5
Gnomad 
frequency
0 0.0000070 (2 
cases)
0 0 0 0
CADD-Phred 
score
26.0 31 40 27.3 33 28
GERP 5.36 4.94 4.8 4.92 3.97 4.92
MutationTaster Disease causing Disease causing Disease causing (1) Disease causing N/A Disease causing (1)
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FATHMM Damaging (-5.14) Damaging (-2.17) Damaging  (0.977)
(FATHMM-MKL)







N/A Probably Damaging (1)
Growth OFC 40 cm (1st)
Weight 3kg (64th)
OFC 52cm (6th )
weight 29.8kg 
(39th)
Height 139 cm 
(59th) 
OFC 55cm (46th)
Height 165 cm 
(65th)
OFC 51.8 cm 
(82nd)
Weight 26 kg (2nd - 
9th)
OFC 46 cm (<0.4th) 
OFC 59 cm
Height 174 cm (36th)
Weight 64kg (27th)
Neurology












Speech 6 years 
Intellectual 
disability
Severe Mild Severe None Severe Severe
Autism No Yes Yes No No Yes
ADHD No No No No No No
Epilepsy No No No No No No
Motor N/A N/A Stereotypies 
Hypotonia 
Spastic diplegia Spastic quadriplegia
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Hearing BLSNHL Not assessed BLSNHL Normal Normal Normal 
Ocular Unilateral iris 
coloboma
No No No No No
Cardiac Defect Ventricular septal 
defect
No No No No No
Gastrointestinal Tracheo-
esophageal fistula
No Reflux No Unsafe swallow, 
gastrostomy feed 
No
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Case 7 Case 8 Case 9 Case 10 
(Macnamara)
Case 11 (Delpire)



















c.2938G>A c.2935G>A c.2935G>A N/A c.3076_3086del
ACMG 4 4 4 N/A 5







p.(Glu980Lys) p.(Glu979Lys) p.(Glu979Lys) N/A p.(Val1026PhefsTer2
)
Exon (of 28) 21 21 21 2-7 22
Gnomad 
frequency
0 0 0 0 0
CADD-Phred 
score
23 23 23 N/A 36
GERP 5.11 5.11 5.11 N/A 4.96
MutationTaster Disease causing (1) Disease causing (1) Disease causing (1) N/A N/A
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Growth OFC 59.5 cm 
(48th)











Weight 33.9kg (41st) 
Neurology
Brain MRI Normal N/A Normal Cortical atrophy N/A














None None None Severe None
Autism No No No N/A No
ADHD No No No N/A No
Epilepsy No No No EEG abnormal Seizure like episodes
EEG abnormal
Motor Hypotonia Normal Normal Hypotonia Hypotonia
Myoclonus
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Hearing BLSNHL BLSNHL BLSNHL BLSNHL Normal 






Cardiac Defect No No No No Dilated 
cardiomyopathy 





Respiratory No No No Choanal atresia No
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Supplementary table 1.  SLC12 gene family members and human disease.
Gene Expression pattern Disease Phenotype
SLC12A1 Renal medulla 
Renal cortex 
Bartter syndrome (OMIM 601678) Hypokalaemia
Hypotension 






Gitelmann syndrome (OMIM 263800) Hypokalaemia
Alkalosis 




SLC12A5 Brain only Epileptic encephalopathy (OMIM 
606726)
Epilepsy 
SLC12A6 Brain, Renal, GIT, 
vasculature, lung, 
glandular tissue
Andermann syndrome (OMIM 21800) Neuropathy, agenesis 
of corpus callosum, 
intellectual disability







SLC12A9 Predominantly spleen No known disease
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Supplementary table 2. Additional de novo variants in patients with SLC12A2 variants.



























N/A (father of case 9)
Case 9
(AF)
NPEPPS   (17-45669435_45669437dup)
OR2T8 (1-248084798-C-T)
Both predicted benign 
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Ascertainment of individuals with SCL12A2 variants
Exome sequencing in the DDD study (Wright et al., 2015) has UK Research Ethics Committee 
approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by 
the Republic of Ireland REC). For trio exome sequencing in the DDD study, saliva samples 
were collected (Oragene DNA collection kits, DNA Genotek, Kanata, ON, Canada) and DNA 
extracted (QIAsymphony, Qiagen, Venlo, Netherlands). Exome sequencing was performed at 
the Wellcome Trust Sanger Institute with Agilent SureSelect 55MB Exome Plus with Illumina 
HiSeq to investigate single nucleotide variants (SNVs) and small insertion-deletions (indels) 
in coding regions of the genome. An automated variant pipeline was used as previously 
described (Wright et al., 2015). Probands with protein altering SNVs in SLC12A2 were 
identified in patients 1-5. Further individuals with SLC12A2 SNVs were identified via 
Genematcher.  For patients 8 and 9 trio exome sequencing was performed using Roche® 
NimbleGen Medexome commercial kit (SeqCap® EZ Human Exome Probes v3.0) on a 
Illumina® NextSeq instrument.  Variants were validated by Sanger sequencing for cases 6-9. 
In silico assessment of pathogenicity of SCL12A2 variants 
The effects of variants in SLC12A2 were assessed using Combined Annotation Depletion 
Dependent score (CADD)(Rentzsch et al., 2019), MutationTaster (Schwarz et al., 2010), 
FATHMM (Shihab et al., 2013)and PolyPhen-2 (Shihab et al., 2013). The presence of 
SLC12A2 variants in human populations without NDD was queried using gnomAD. The excess 
in occurrence of de novo SLC12A2 protein-altering (nonsynonymous and loss-of-function) 
variants in DDD was assessed using DenovolyzeR, an open source R package (Ware et al., 
2015). We used Denovolyzer with default parameters, number of subjects 9856 and DNM 
expected rate 0.8. The obtained p-value was then corrected for multiple testing with Bonferroni 
accounting for 19618 genes. Spatial clustering of missense SLC12A2 DNMs was assessed 
using Denovonear, a python script that calculates the probability that DNMs within a gene 
cluster together based on per-gene mutability rate through one million simulations weighted by 
the context trinucleotide rate. We used MuPiT to map DNMs onto protein structure (Niknafs 
et al., 2013).
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Transcriptomic study of SLC12A2 expression in developing human brain
Variations in SLC12A2 transcript levels in the human brain among different developmental 
stages and anatomical regions were investigated using RNA microarray data from the 
BrainSpan Atlas of the Developing Human Brain (Miller et al., 2014). Single cell RNA 
(scRNA) sequencing data from the human brain at 16-18 weeks gestation was obtained 
from(Pollen et al., 2015).  NetworkAnalyst was  used to explore transcriptomic differences in 
scRNA data between SLC12A2 expressing and non-expressing cells (Xia et al., 2015). 
In silico study of expression of SLC12A2 splice isoforms 
RNA-seq data was downloaded from BrainSpan as a .csv file.  Exon expression is reported in 
normalised form and quantified as CPM. The ratio of exon 21 to mean expression of all other 
exons was calculated to quantify expression of exon 21 containing transcripts.  An  exon 
21:(mean expression exons 1 - 28) ratio <1.0 is taken to indicate the presence of transcripts 
which do not contain exon 21. Long-read RNA-seq data from developing mouse cochlea was 
queried using the internet portal (https://morlscrnaseq.org/).  Evidence of alternative splicing 
of exon 21 was sought by visualising Sashimi plots (Ranum et al., 2019).    
In vitro assessment of NKCC1 ion transporter function
NKCC1 function was assessed through K+ influx measurements into Xenopus laevis oocytes 
injected with wild-type or mutant NKCC1 cRNA (Delpire et al., 2011). All procedures 
involving animals were approved by Vanderbilt University Medical Center IACUC. Single 
oocytes were isolated from Xenopus laevis ovarian lobes using collagenase treatment (4 x 1.5 
hr incubation with 10 mg/ml Collagenase D) and incubated overnight in L15 medium (250 ml 
Leibovitz medium + 200 ml water + 752 mg HEPES, pH 7.4, + 44 ug/ml gentamicin) at 16oC. 
The following, day, groups of 20-25 oocytes were injected with 50 nl water containing 15 ng 
NKCC1 cRNA and returned to 16oC for 3 days. Unidirectional K+ influx was measured using 
Rb-86 isotope as tracer. Oocytes were first washed in a solution containing in mM: 96 NaCl, 4 
KCl, 1 Ca2Cl, 0.8 MgSO4, 5 HEPES, pH 7.4, 200 mOsM, then preincubated for 15 min in 
identical solution containing 1 mM ouabain. The preincubation was then aspirated and oocytes 
were incubated in same ouabain-containing solution (or same solution made hypertonic with 
addition of 65 mM sucrose) with 5 uCi/ml Rb-86 for 1 hour.  After 4 rapid washed with ice-
cold solution, individual oocytes were placed in vials and lyzed with 200 ul 0.25N NaOH for 
1 h, followed by 100 ul glacial acetic acid and 5 ml scintillation liquid. Aliquots of 5 ul of flux 
solutions were also counted to translate cpm into pmoles K+. K+ influx was expressed in 
pmoles/oocyte/hr.
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Gene co-expression network analysis 
From the scRNA data obtained from (Pollen et al., 2015) we dichotomised cells into those 
robustly expressing SLC12A2 and those with a count of 0 for SLC12A2. We then used 
NetworkAnalyst’s “Gene Expression Table” function to upload normalised scRNA count data 
from SLC12A2 expressing and non-expressing cells. Data was filtered with a variance filter of 
15 and to remove low abundance transcripts. Data was not normalised as the data from Pollen 
et al was normalised prior to publication. Differential gene expression analysis was then 
performed (p<0.05, FDR 5%). This identified 589 differentially expressed genes. A gene co-
expression network was then created, using the tissue specific setting (brain cortex). The 
network was created using the minimum setting, creating a network of 947 notes and 332 seeds. 
The network was visualised with autolayout and the reduced overlap setting. The label 
propagation algorithm was then used to identify 5 modules within the network. Function 
explorer was then used to perform an enrichment analysis of the modules.      
Supplementary Results
Case reports
Patient 1 (270188) is a 12 month old boy with multiple congenital anomalies (iris coloboma, 
ventricular septal defect and tracheo-oesophageal fistula), the first child of non-
consanguineous parents.  Mother had unilateral coloboma but no NDD. He was born at 37 
weeks gestation and spent a period of time in a special care baby unit due to feeding 
difficulties. At 12 months of age his weight was 3 Kg (64th percentile), length 68cm (1st 
centile) and orbito-frontal circumference 40 cm (1st percentile). At 12 months he had not sat 
independently or spoken any words. He had bilateral sensorineural deafness. Cranial 
magnetic resonance imaging (MRI) demonstrated cortical dysplasia. Comparative genomic 
hybridisation (CGH) was normal. Trio exome sequencing identified a de novo, heterozygous 
missense variant in SLC12A2 (g.127450305C>T, p.(Ala327Val)).  
Patient 2 (DDD4K.02331) is a 9 year old boy with a NDD consisting of autism and mild 
intellectual disability. He was born at term. There was no clinical evidence of hearing 
impairment.  CGH was normal. Cranial MRI was not performed. Trio exome sequencing 
demonstrated a de novo, missense variant in SLC12A2 (g.127469897G>A
, p.(Arg410Gln)).
Page 27 of 37
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
Patient 3 (278327) is a 15-year old girl with a NDD consisting of global developmental delay, 
autism, motor stereotypy and hypotonia.  She had bilateral sensorineural hearing impairment. 
She was born at 40 weeks gestation with initial feeding difficulties associated with reflux. At 
15-years old her height was 165 cm (65th centile) and orbitofrontal circumference 55 cm (46th 
centile). She first walked age 3 years and was non-verbal. Cranial MRI was not performed. 
CGH was normal. Trio exome sequencing identified a de novo, heterozygous nonsense variant 
in SLC12A2 (g.127503511G>A, p.(Trp892*)).  
Patient 4 (293333) is a 3 year and 4 months old girl with a NDD consisting of spastic 
paraparesis and delay of speech and gross motor development. She did not have any hearing 
impairment. She was born at 40 weeks of gestation, there were no neonatal complications.  At 
3 years old her orbitofrontal circumference was 51.8 cm (82nd centile). A cranial MRI scan 
was reported as normal.  CGH was normal. Trio exome sequencing identified a de novo, 
heterozygous missense variant in SLC12A2 (g.12746683A>T, p.(Asn376Ile)). 
Patient 5 (296317) is a 6 year old girl with a NDD consisting of severe global developmental 
delay. She was born at 39 weeks gestation and spent a period of time in a special care baby unit 
with nasogastric feeding. Her neonatal hearing assessment using AOAE and AABR showed 
clear responses bilaterally. Subsequently a percutaneous feeding tube was fitted because of an 
unsafe swallow. She has muscle hypertonia of all four limbs. She had left hip dislocation 
corrected with open reduction and left femoral osteotomy. She has a thoracolumbar scoliosis. 
She does not walk independently and is non-verbal. Cranial MRI demonstrated agenesis of the 
corpus callosum. CGH was normal. Trio exome sequencing demonstrated a frameshift variant 
in SLC12A2 (g.127420201dup, p.(His186fs16)).  
Patient  6 is a 21-year old boy with a NDD consisting of autism and intellectual disability. He 
is the only child of unrelated and healthy parents. Parents experienced three spontaneous 
abortions in the first trimester of gestation. He was born at term and showed a normal perinatal 
clinical history. He showed an almost normal motor development with ambulation acquired at 
13 months. At two years of age he was diagnosed with autism spectrum disorder. Language 
was acquired at 6 years of age. Hearing tests were all normal. At 21 years height was 174 cm 
(36th centile), weight 64 Kg (27th centile) and orbitofrontal circumference 59 cm (+2.7 SD).  
Karyotype, oligo-array-CGH and FMR1 triplet expansion region analysis were all normal. Trio 
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exome sequencing demonstrated a de novo, missense variant in SLC12A2 (g.127466845G>C, 
p.Ala379Leu).
Patient 7 is a 25-month old boy with hypotonia, tongue fasciculation and developmental delay. 
He is the 4th child of healthy, non-consanguineous parents. He was born at term and failed his 
newborn hearing test.  He has bilateral sensorineural hearing impairment with cochlear implant 
placed at 1-year of age.  Nystagmus and tongue fasciculation were initially present but resolved 
by 1-year of age. Formal ocular examination was normal. At 25-months height was 87 cm (47th 
centile), weight 13 Kg (62nd centile) and orbitofrontal circumference 49.5 cm (48th centile).  
He walked independently at 25-months of age.  He had speech delay associated with hearing 
impairment.  A SNP-array demonstrated 47, XYY. Cranial MRI was normal. Trio exome 
sequencing demonstrated a de novo, missense variant in SLC12A2 (g.127512895G>A, 
p.(Glu980Lys)).  
Family S1585 (patient 8 and 9). Fath r and son affected by BNSHL with bilateral congenital 
vestibular areflexia with dominant pattern of inheritance. Cognitive abilities were not tested. 
Patient II.1(case 9), a full-term baby, presented with a congenital bilateral profound NSHL, 
revealed by abnormal neonatal hearing screening. He is the only child of unrelated parents.
Unilateral cochlear implant was provided at age of two. Cranial growth showed a posterior 
plagiocephaly. Age of walking was 24 months old. Vestibular assessment was difficult but 
rotational vestibular ocular reflex was absent, suggesting a bilateral vestibular areflexia. His 
father (case 8), a 44 year old man, presented with a bilateral profound hearing loss and a 
bilateral vestibular areflexia (confirmed by video head impulse test, videonystagmography and 
absence of vestibular evoked myogenic potentials). The father’s age of walking was 18 months 
old, which suggested a congenital onset of vestibular areflexia. Bilateral hearing aids were 
fitted at the age of 3 and were still used, only providing environmental sounds perceptions. The 
father’s communication was sign language. He obtained a training vocational certificate and 
worked as a car washer. Trio exome sequencing demonstrate a missense variant segregating in 
SLC12A2 (g.127512802G>A, p.(Glu979Lys)).  The father was the only affected out of 7 
siblings and his parents did not suffer hearing loss. 
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NKCC1 Flux analyses results
As seen in Figure S2, alanine at position 327 which is located towards the middle of 
transmembrane domain 2 (TMD2), is highly conserved within NKCC1 but not conserved 
among the different members of the Slc12a transporters. Mutation into valine (as in patient 1) 
results in a significant reduction in transport activity under both basal and stimulated conditions 
(Figure 2). As seen in Figure S1, arginine at residue 410 is a positively charged residue located 
within TMD4, highly conserved among the different NKCC1s and among the functionally well 
characterized cation-chloride cotransporters. Its mutation into glutamine (as in patient 2) 
decreased K+ influx under both basal and stimulated conditions, but only by ~30% (Figure 2). 
The mutation from patient 3 (p.Trp892*) was tested next. The residue is located within the 
cytosolic COOH-terminal tail of the cotransporter and is highly conserved among all NKCC1 
proteins listed and also among the different cation-chloride cotransporters (Figure S2). 
Termination of translation at that position results in a complete loss of NKCC1 function (Figure 
2). The fourth mutation involves another transmembrane domain (TMD3) residue: asparagine 
at position 376. The asparagine is highly conserved within the Na+-dependent cotransporters, 
while it is a conserved threonine in th  Na+-independent K-Cl cotransporters (Figure S1). 
Mutation into an isoleucine results in a significant decrease in NKCC1 function. Interestingly, 
the function is completely inexistent under basal or isotonic conditions but reduced by half 
under stimulated or hypertonic conditions (Figure 2). Patient 5 carries a mutation that 
terminates translation of the cotransporter open reading frame early within the cytosolic N-
terminus. The mutation causes a frameshift causing the appearance of 16 new amino acids 
followed by a stop codon p.(His186AlafsTer17). Irrespective of this addition, the protein if 
translated, terminates before the first transmembrane domain, and thus no transport function 
can be associated to this fragment. As seen in Figure S1, the next mutant is located within the 
much less conserved carboxyl-terminal tail of NKCC1. It is part of a stretch of 4-5 negative 
residues that are mostly conserved from shark to human. Its mutation into lysine 
(p.(Glu980Lys), patient 7) significantly affected the level of flux under isosmotic (basal) 
conditions, but the cotransporter could be maximally stimulated by hypertonicity (Figure 2). 
Our last mutant from patient 6, p.(Ala379Leu), involves a residue in TMD3 that is neighboring 
the asparagine (at 376) mutated in patient 4. As seen in Figure 2, mutation of this conserved 
residue causes severe reduction in NKCC1 function under both basal and stimulated conditions.  
The effect of the p.(Glu979Lys) variant was not tested. However, we predict it to be deleterious 
based upon in silico analyses and the fact that the adjacent p.(Glu980Lys) variant reduces flux.
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Figure 1. SLC12A2 missense variants.   
A. Chart summarising frequency of clinical features in children with SLC12A2 de novo mutations and a NDD. 
B. Schematic representation of NKCC1 with 12 transmembrane domains and inverted 5 TMs + 5 TMs 
symmetry (shaded TMs), followed by TM11 and TM12 (white TMs). The position of patient mutations is 
indicated in red. C. Three dimensional structure of NKCC1 demonstrating location of missense variants at 
core of protein, with high potential to disrupt protein structure. 
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Figure 2. Functional analysis of NKCC1 mutation in Xenopus laevis oocytes. A-B. Box plots demonstrating 
K+ influx measured in oocytes injected with water (negative control), water containing 15 ng wild-type 
(control) or mutant mouse NKCC1 cRNA. Horizontal line represents median, extent of box demonstrates 
interquartile range and whiskers minimum and maximum. K+ fluxes were measured under basal isosmotic 
(200 mOsM) or stimulated hyperosmotic (270 mOsM) conditions and are expressed in pmoles K+ per oocyte 
per hour.  As the mutants were tested in different experiments on different oocytes, each mutant flux is 
accompanied by its own control flux. Statistical differences were determined using one way ANOVA. Each 
experiment represents 20-25 oocytes per mutation. Note that the mouse residue numbers are slightly 
different from human. 
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Figure 3. Transcriptomic analysis of SCL12A2 expression in developing human brain. 3a. Box plots of 
microarray data comparing SLC12A2 expression in neuroanatomical regions of high and less active 
neurogenesis at 15 weeks gestation. Horizontal lines represent median, extent of box interquartile range 
and whiskers minimum and maximum.  Expression is significantly higher in areas of active neurogenesis (*). 
 3b. Single cell RNA sequencing data demonstrating significantly higher expression of SLC12A2 in radial glia 
cells (RGC) compared to intermediate progenitor cells (IPC)(mann-whitney u-test, Z = -3.3, p = 0.001) and 
neurons (z = -5.2, p < 0.001).  Units are counts per million reads (CPM). 
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Figure S1. SLC12A2 splice isoforms. 
Eight SLC12A2 isforms are identified by GTEx https://www.gtexportal.org/home/gene/SLC12A2.  Note 
canonical isoform ENST00000262461.6 has 27 exons.  ENST00000343225.4 has exon 21 spliced out and 
represents the minor isoform found in the developing brain.   
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Figure S2. Sequence alignment of SLC12 gene family members. 
The amino acid sequences of NKCC1 from eight species were aligned using VectorNti Suite 6.0 (Invitrogen). 
Portions representing the regions of interest were selected as follows: in A, a portion of TMD2 highlighting 
the conservation of the Ala327 residue; in B, a portion of TMD4 showing conservation of Arg410; in C, 
amino acids within a portion of the carboxyl-terminus showing conservation of Trp892; in D, portion of TM3 
showing conservation of residues Asn376 and Ala377; and in E, a portion of the carboxyl-terminus showing 
some degree of conservation of residues Glu979 and Glu980. To assess conservation between the different 
members of the SLC12A gene products, the amino acids from human NKCC1, NKCC2, NCC, and KCC1-4 
were also aligned. In F, residue Ala327 is less conserved among the different cotransporters; in G, Arg410 is 
highly conserved; in H, Trp758 is also a highly conserved residue; and in I, Asn376 and Ala377 are only 
conserved within the Na+-dependent cotransporters. Identical residues across are highlighted by yellow 
background, whereas conserved substitutions are shown in green or blue background. Non-conserved 
residues are shown in white background.   
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Figure S3. Expression of alternatively spliced exons and isoforms of SCL12A2. 
a. The ratio of exon 21 expression to expression of all other 27 exons of SLC12A2 is <1.0 in the first and 
second trimester of pregnancy.  This demonstrates the presence of transcripts which do not contain exon 
21. 
b. Image captured from https://morlscrnaseq.org/ an atlas of long-read single cell RNA expression data 
from murine inner ear.  Sashimi plot demonstrates no alternative splicing events at exon 21.  The only 
transcript expressed in mouse cochlea therefore contains exon 21. 
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Figure S4. Gene co-expression network analysis of single cell RNA data from SLC12A2 expression cells. 
A. Figure shows module 1 identified by gene co-expression network based on differentially expressed genes 
created by NetWorkAnalyst.   The degree filter was used so that only hub genes are shown in this figure. 
B. Table of significantly enriched terms for whole network. 
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